Topic: checkpoint inhibitors
Sanofi and Regeneron's Libtayo may be the sixth in its class to launch, but it already has something not all its rivals do: a market all to itself.
AstraZeneca already has an Imfinzi OK in lung cancer maintenance. But new survival data will strengthen its case—and its lead over its I-O rivals.
Roche is looking to snag a $1 billion piece of the lung cancer market for its own, and it now has survival data to back up its bid.
Roche has been chomping at the bit to challenge Merck in previously untreated lung cancer, but it’s going to have to wait a little longer.
England's cost watchdog has decided Merck’s blockbuster Keytruda is not a good treatment choice in Hodgkin lymphoma—at least not for all patients.
Merck is getting ready to take on Pfizer and Merck KGaA’s Bavencio in a rare form of skin cancer, and the FDA just sped up the showdown.
Industry watchers expected Merck's Keytruda-chemo combo to win a full approval in first-line lung cancer. But they may not have expected it this soon.
Bristol-Myers Squibb may be trailing rival Merck in the non-small cell lung cancer market, but it has landed a niche of its own in the small cell arena.
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.